NEWPORT COAST, Calif., Oct. 20, 2020 /PRNewswire/ — VivoSense, Inc. is proud to announce that we have been awarded an NIH/NCI Phase 1 contract to develop software enabling data integration from wearable sensors for cancer patients. The contract will result in the development of the VivoSense Cancer Health Informatics Platform as the leading wearable sensor agnostic cloud platform for cancer research and clinical care.
Wearables Provide New Insight into Cancer Research & Treatment
Although cancer remains one of the most devastating diseases, the past decade has brought enormous progress, particularly in the field of immunotherapy. However, breakthrough cancer therapeutics do not benefit all patients equally. Wearables have created an opportunity to gain more insight into the factors contributing to this outcome. The unprecedented amount of patient-specific, real-world data from wearable sensors opens the door to rethink how clinical trials can advance personalized treatment strategies.
Patient monitoring and the precise delivery of cancer care improves outcomes and the management of symptoms and side-effects. With robust wearable sensor solutions, care providers will have the ability to passively and continuously monitor multiple behavioral and biological parameters that can be used to adjust and optimize treatment strategies throughout care. As patients with cancer live longer, it is vitally important to understand and develop treatment regimens that maintain patient quality of life.
A Scalable Data Analysis Platform is Fundamental
The opportunity to translate real-world data into actionable information that advances earlier diagnosis and precise treatment options in cancer patients is a huge step forward for cancer research. With this award, we will engage key opinion leaders at every step and build an end-to-end data informatics platform explicitly designed for cancer research and care communities.
“Wearable sensors and digital biomarkers have the potential to revolutionize cancer research and care. Our ten years of wearable sensor analytics experience ideally positions VivoSense to deliver on this award with an innovative cancer-specific analytics platform,” stated Kate Lyden, PhD, Principal Investigator and VivoSense’ VP of Science and Research.
If you are an oncology investigator, drug developer or care provider interested in evaluating wearable sensors in your studies, contact Dr. Kate Lyden kate.lyden@vivosense.com to discuss your specific research needs.
Phase 1 of this project has been funded in whole (100%) with Federal funds in the amount of $392,519 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N91020C00058.
Download the 4 Key Principles of Digital Biomarker Development ebook to learn more about how to realize the potential of wearable sensor data in your clinical trial.
Contact: Krista Moon, krista@ascendbusinessgrowth.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/vivosense-awarded-the-nihnci-grant-to-aid-in-cancer-research-301155151.html
SOURCE VivoSense, Inc.
Two immersive 2026 events in Seattle and Boston will offer up to 12 CE credits,…
Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth…
Study published by Centre for Neuro Skills researchers in Brain Injury journal argues current insurance…
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large,…
American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as…
TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard”…